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Abstract 30 
Objective: The aim of this study was to examine the association between body mass index 31 
(BMI) and risk of incident hypertension among Japanese men and women who are 32 
middle-aged and older. 33 
Design: Prospective, population-based cohort study. 34 
Subjects: A total of 68 205 non-hypertensive adults (18 336 men and 49 869 women) aged 35 
40-79 years who completed health check-ups in the Ibaraki prefecture, Japan, in 1993 were 36 
followed-up through 2006. To exclude the impact of BMI change during the follow-up period, 37 
a time-dependent covariate Cox proportional hazards model was used to compute the hazard 38 
ratios (HRs) of incident hypertension according to BMI categories. Incident hypertension was 39 
defined as a systolic blood pressure (BP) of ≥ 140 mmHg, a diastolic BP of ≥ 90 mmHg, 40 
and/or hypertensive medication use. 41 
Results: A total of 30 982 adults (45.4%) developed hypertension (9 331 men and 21 651 42 
women) during a mean of 3.9 years of follow-up. Compared with a BMI of < 19.0, 43 
time-dependent covariates adjusted HRs (95% confidence interval [CI]) for hypertension 44 
among participants with a BMI of ≥ 25.0 were 1.42 (1.17-1.73) for men aged 40 to 59 years, 45 
1.34 (1.19-1.51) for men aged 60 to 79 years, 1.47 (1.33-1.62) for women aged 40 to 59 years, 46 
and 1.29 (1.18-1.41) for women aged 60 to 79 years. 47 
Conclusion:
51 
 The baseline BMI is associated with future risk for incident hypertension even 48 
after accounting for weight change during the follow-up period. Weight loss may be 49 
recommended to non-hypertensive obese adults to prevent the development of hypertension. 50 
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Introduction 52 
Hypertension is a major cause of cardiovascular disease [1]. Currently, approximately 45% of 53 
Japanese adults are considered hypertensive [2], defined as systolic blood pressure (SBP) ≥ 54 
140 mmHg, diastolic blood pressure (DBP) ≥ 90 mmHg or treatment with an 55 
antihypertensive drug. Many prospective cohort studies have consistently shown that the 56 
higher the BMI, the greater the likelihood of developing hypertension [3-11]. Some 57 
prospective cohort studies have reported that long-term weight gain was associated with a 58 
risk of hypertension among hypotensive or high-normal blood pressure patients [12-15]. 59 
Moreover, many intervention studies have also shown that weight loss reduced blood 60 
pressure [16-18]. These results could lead to a hypothesis that the association between 61 
baseline BMI and the risk of hypertension are due to weight gain during the follow-up period. 62 
If this hypothesis were true, non-hypertensive obese individuals would not be required to lose 63 
weight to prevent incident hypertension. To clarify whether weight loss should be 64 
recommended for non-hypertensive obese people to prevent incident hypertension, a large 65 
cohort study that accounts for weight change is warranted. The purpose of this study was to 66 
clarify the association between long-term weight stability and the risk of incident 67 
hypertension in a large community-based cohort of men and women who are middle-aged 68 
and older.  69 
70 
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Methods 71 
Study population 72 
The study population comprised 194 333 individuals (63 865 men and 130 468 women) aged 73 
40-79 years living in the Ibaraki Prefecture, Japan. The population participated in 74 
community-based annual health checkups beginning in 1993 (Ibaraki Prefectural Health 75 
Study). These health checkups were conducted by local governments in accordance with the 76 
Japan Health Laws. Data were collected by the Ibaraki prefectural government from local 77 
governments after depersonalizing them to ensure anonymity. We excluded 3 080 individuals 78 
(738 men and 2 342 women) with incomplete data and 94 153 individuals (35 647 men and 79 
58 506 women) with a SBP of ≥ 140 mmHg and/or a DBP of ≥ 90 mmHg or antihypertensive 80 
medication use. We further excluded 28 895 individuals (9 144 men and 19 751 women) who 81 
did not participate in the 1994 survey, thereby ensuring that the participants were followed 82 
for at least one year. 83 
Ultimately, the study subjects consisted of 68 205 individuals (18 336 men and 49 869 84 
women). These participants were followed up by annual examinations until hypertension had 85 
been diagnosed or until the end of 2006. Blood pressure was measured at annual follow-up 86 
examinations. Participants who did not undergo annual checkups during the follow-up 87 
periods were censored on the date of their latest checkup. The protocol for this cohort study 88 
was approved by the Ibaraki Epidemiology Study Union Ethics Review Committee. 89 
 90 
Assessment of body mass index, blood pressure, and other covariates 91 
Height in stockinged feet and weight in light clothing were measured at baseline. BMI was 92 
calculated as weight in kilograms divided by the height in meters squared. BP was measured 93 
from the right arm of seated participants who had rested for more than 5 minutes by trained 94 
observers using standard mercury sphygmomanometers during examinations that occurred 95 
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between 1993 and 2004 and by an automated sphygmomanometer between 2005 and 2006. 96 
When the SBP was greater than 150 mmHg or DBP was greater than 90 mmHg, a second 97 
measurement was performed after several deep breaths, and the lower values, which were 98 
almost always observed after the second measurement, were used for analyses. 99 
  Blood samples were drawn from seated participants into two polyethylene terephthalate 100 
tubes: one with an accelerator and the other with sodium fluoride and 101 
ethylenediaminetetraacetic acid. Overnight fasting (≥ 8 hours) was not required. The blood 102 
glucose level was measured by the glucose oxidase electrode method with a GA1140 device 103 
(Kyoto Daiichi Kagaku, Kyoto, Japan) during examinations that occurred between 1993 and 104 
1996, by the enzyme method with a H7170 device (Hitachi, Tokyo, Japan) between 1997 and 105 
2003, and with a H7700 device (Hitachi, Tokyo, Japan) between 1994 and 2006. Participants 106 
were considered diabetic if they had a fasting plasma glucose level of at least 6.1 mmol/L or a 107 
non-fasting glucose level of at least 7.8 mmol/L, or if they were being treated for diabetes 108 
mellitus. Serum total cholesterol and serum triglyceride levels were measured by the enzyme 109 
method with a RX-30 device (Nihon Denshi, Tokyo, Japan) between 1993 and 1995, with a 110 
H7350 device (Hitachi, Tokyo, Japan) between 1996 and 2003, and with a H7700 device 111 
between 2004 and 2006. High-density lipoprotein (HDL) cholesterol levels were measured by 112 
the phosphotungstic acid magnesium method with a MTP-32 device (Corona Electric, Ibaraki, 113 
Japan) between 1993 and 1995, by the selective inhibition method with a H7350 device 114 
between 1996 and 2003, and with a H7700 device between 2004 and 2006. The laboratory 115 
participated in external standardization and successfully met the criteria for precision 116 
accuracy for the measurement of blood samples by the Japan Medical Association, the 117 
Japanese Association of Medical Technologists, and the Japan Society of Health Evaluation 118 
and Promotion. An interview was conducted to ascertain medical history, smoking status 119 
(never, ex-, current < 20 cigarettes/day, and ≥ 20 cigarettes/day), and alcohol intake (non-, 120 
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sometimes, < 66 g/day, and ≥ 66 g/day). 121 
 122 
Endpoint determination 123 
Incident hypertension was defined as SBP of ≥ 140 mmHg, DBP of ≥ 90 mmHg, and/or when 124 
treatment for hypertension was initiated. 125 
 126 
Statistical analysis 127 
Participants were classified into the following 7 categories with regard to their BMI: < 19.0, 128 
19.0-20.9, 21.0-22.9, 23.0-24.9, 25.0-26.9, 27.0-29.9, or ≥ 30.0 kg/m2. Baseline participant 129 
characteristics were compared according to BMI categories using chi-squared tests for 130 
categorical variables and analysis of variance for continuous variables. Hazard ratios (HRs) 131 
with 95% confidence intervals (CIs) for incident hypertension relative to BMI categories 132 
were calculated with a reference of < 19.0 kg/m2 using a Cox proportional hazards regression 133 
model [19]. The analyses were stratified by sex and age groups (40-59 and 60-79 years).  134 
Three multivariable-adjusted models were used. In Model 1, covariates included age 135 
(years), SBP (mmHg), DBP (mmHg), fasting status (yes or no), total cholesterol level 136 
(mmol/L), HDL cholesterol level (mmol/L), log-transformed triglyceride level (mmol/L), 137 
lipid medication use (yes or no), blood glucose status (normal: < 6.1 mmol/L during fasting 138 
or < 7.8 mmol/L during non-fasting; border: 6.1-7.0 mmol/L during fasting or 7.8-11.1 139 
mmol/L during non-fasting; hyperglycemia: ≥ 7.0 mmol/L during fasting or ≥ 11.1 mmol/L 140 
during non-fasting), smoking status (never, ex-, current < 20 cigarettes/day, or ≥ 20 141 
cigarettes/day), and alcohol intake (non-, sometimes, < 66 g/day, or ≥ 66 g/day). In Model 2, 142 
the changes in BMI, total cholesterol level (mmol/L), HDL cholesterol level (mmol/L), and 143 
log-transformed triglyceride level (mmol/L) from baseline to the end of follow-up were 144 
added as covariates to Model 1. In Model 3, time-dependent variables of BMI and covariates 145 
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in Model 1 were used with a time-dependent Cox hazard model, which was used for adjusting 146 
the change in the variable from the baseline to the final year of follow-up [20]. For the 147 
secondary analysis, we excluded 34 190 participants with incomplete data and 16,370 148 
participants with a SBP of ≥ 140 mmHg and/or a DBP of ≥ 90 mmHg or antihypertensive 149 
medication use at a 5-year follow-up. The remaining 17 645 qualified participants were 150 
classified into the following 4 categories with regard to their baseline BMI and BMI 5 years 151 
later: (a) BMI of less than 25 kg/m2 at baseline and BMI of less than 25 kg/m2 at a 5-year 152 
follow-up (-/-); (b) BMI of 25 kg/m2 or more at baseline and BMI of less than 25 kg/m2 at a 153 
5-year follow-up (+/-); (c) BMI of less than 25 kg/m2 at baseline and BMI of 25 kg/m2 or 154 
more at a 5-year follow-up (-/+); and (d) BMI of 25 kg/m2 or more at baseline and BMI of 25 155 
kg/m2 or more at a 5-year follow-up (+/+). We calculated HRs for incident hypertension to 156 
consider long-term changes of their weights. 157 
All statistical analyses were conducted using SAS, version 9.1 (SAS Institute, Inc., Cary, 158 
North Carolina). 159 
160 
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Results 161 
Sex-stratified baseline characteristics according to BMI categories are shown in Table 1. All 162 
covariates, except for blood glucose status, diabetic medication use and smoking status in 163 
men and lipid medication use in women, were associated with BMI in both sexes. A higher 164 
BMI was linked with higher SBP and DBP at baseline in both sexes. 165 
Of the 68 205 adults (18 336 men and 49 869 women), 30 982 (45.4%) developed 166 
hypertension (9 331 men and 21 651 women) during a mean follow-up of 3.9 years (3.4 years 167 
for men and 4.1 years for women). Table 2 shows sex- and age-stratified HRs for 168 
hypertension according to the baseline BMI categories. In men aged 40-59 years, compared 169 
with a baseline BMI < 19.0 kg/m2, the multivariate HRs of BMI ≥ 25.0 kg/m2 was 170 
significantly higher in Model 1 and Model 2. In men aged 60-79 years, compared with a 171 
baseline BMI < 19.0 kg/m2, the multivariate HRs of BMI ≥ 19.0 kg/m2 was significantly 172 
higher in Model 1 and the multivariate HRs of BMI ≥ 23.0 kg/m2 was significantly higher in 173 
Model 2. In both age groups among men, time-dependent covariates adjustment HRs (BMI ≥ 174 
25.0 kg/m2: 1.42, ≥ 30.0 kg/m2: 1.77 in aged 40-59 years; BMI ≥ 25.0 kg/m2: 1.34, ≥ 30.0 175 
kg/m2: 1.68 in aged 60-79 years) showed a trend similar to Model 1 and Model 2. 176 
In women aged 40-59 years, compared with a baseline BMI < 19.0 kg/m2, the multivariate 177 
HRs of BMI ≥ 21.0 kg/m2 was significantly higher in Model 1 and of BMI ≥ 23.0 kg/m2 was 178 
significantly higher in Model 2. 179 
In women aged 60-79 years, compared with a baseline BMI < 19.0 kg/m2, the multivariate 180 
HRs of BMI ≥ 21.0 kg/m2 was significantly higher in Model 1 and 25.0-26.9 kg/m2 of BMI 181 
was significantly higher in Model 2. In both age groups among women, time-dependent 182 
covariates adjustment HRs (BMI ≥ 25.0 kg/m2: 1.53, ≥ 30.0 kg/m2: 2.07 in age 40-59 years; 183 
BMI ≥ 25.0 kg/m2: 1.47, ≥ 30.0 kg/m2: 1.91 in age 60-79 years) showed a trend similar to 184 
Model 1 and Model 2.  185 
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  Figure 1 represents HRs for hypertension according to the BMI categories at baseline and 186 
at a 5-year follow-up. Among all non-hypertensive participants at baseline and at a 5-year 187 
follow-up, compared with the -/- group, the age-adjusted HRs (95% CI) of +/-, -/+, and +/+ 188 
were 1.12 (1.03-1.41), 1.69 (1.47-1.94), and 1.67 (1.53-1.82), respectively. The multivariate 189 
HRs of +/-, -/+, and +/+ were 1.12 (1.03-1.41), 1.69 (1.47-1.94), and 1.67 (1.53-1.82), 190 
respectively.191 
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Discussion 192 
To the best of our knowledge, the results of the present large prospective study showed that 193 
stable obesity in non-hypertensive individuals was significantly associated with an increased 194 
risk of incident hypertension among men and women who are middle-aged and older. 195 
Previous studies that examined the relationship between BMI and hypertension reported 196 
results consistent with the present study. Many cross-sectional studies showed a 197 
dose-dependent relationship between BMI and the prevalence of hypertension in Caucasian 198 
[5, 21] and Asian [3, 13, 22] populations. Kawada [3] reported that the odds ratios for 199 
hypertension against the lowest quartile of BMI (separated by 20, 25 and 28) were 1.7, 3.6, 200 
and 7.2, respectively, with 95% CIs of 1.2-2.3, 2.5-5.2 and 4.7-11.0, respectively, among 201 
middle-aged men and women (5 346 men and 11 525 women, aged 40-59). Prospective 202 
studies [4, 12, 23] also showed similar results to the present study. The Physicians’ Health 203 
Study (13 563 healthy and non-hypertensive men in U.S.) [4] showed that the HRs (95% CIs) 204 
of developing hypertension for men with a BMI of 22.4-23.6, 23.7-24.7, 24.8-26.4, and >26.4 205 
kg/m2 were 1.20 (1.09-1.32), 1.31 (1.19-1.44), 1.56 (1.42-1.72), and 1.85 (1.69-2.03), 206 
respectively (P for the trend, < 0.001), compared with participants who had the lowest BMI 207 
quintile (< 22.4 kg/m2). A cohort study of U.S. female nurses (82 473 women, aged 30-55) 208 
[12] showed that the multivariate HRs (95% CIs) of developing hypertension for women with 209 
a BMI of 22.0-22.9, 24.0-24.9, 26.0-27.9, and > 31.0 kg/m2 were 1.57 (1.44-1.72), 2.15 210 
(1.97-2.35), 3.33 (3.06-3.62), and 6.31 (5.80-6.87), respectively (P for the trend, < 0.001), 211 
compared with women who had the lowest BMI decile (< 20.0 kg/m2), and an increase in 212 
BMI of 1 kg/m2 was associated with a 12 % increased risk for incident hypertension. These 213 
results suggested a strong association between higher BMI and increased risk of incident 214 
hypertension in men and women.  215 
We also examined the effect of 5-year changes in BMI category (BMI less than, or equal or 216 
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more than 25 kg/m2) on incident hypertension. The HRs of non-obese people at a 5-years 217 
follow-up, despite obesity at baseline, was not significant compared with non-obese people at 218 
both baseline and at a 5-years follow-up. In contrast, the HRs of obese individuals at a 5-year 219 
follow-up, despite non-obesity at baseline, was significantly higher compared with non-obese 220 
people at both baseline and at a 5-years follow-up. The effect of change in BMI on blood 221 
pressure has already been examined in some studies [12-18]. A systematic review [24] of 222 
lifestyle intervention studies reported differences ranging from -11 to + 4 kg for weight, -7 to 223 
+ 2.2 mmHg for DBP and -13 to + 6.1 mmHg for SBP. It is suggested that SBP differences 224 
were equal to a ratio of 1 kg to every 1 mmHg. These studies suggest the efficacy of weight 225 
loss for the hypertensive obese population. The present study further represented the efficacy 226 
of weight loss for the non-hypertensive obese population to prevent incident hypertension. 227 
Williams [25] examined the relationship between long-term stable individuals’ BMI (change 228 
less than ± 0.4 kg/m2) and the cumulative incidence of hypertension and showed that the odds 229 
ratio of each kg/m2 increment in baseline BMI was 1.19 (95% CIs: 1.14-1.24) in men and 230 
1.11 (95% CIs: 1.02-1.20) in women. Matsuo et al [26] reported in a cohort study of 5 201 231 
Japanese middle-aged male employees using of a time-dependent Cox proportional hazard 232 
model for analysis that the HRs (95% CIs) of stable BMI of 25.0-26.9, 27.0-29.9, and ≥ 30.0 233 
kg/m2 were 1.11 (0.93-1.32), 1.34 (1.09-1.65) and 1.49 (1.09-2.04), respectively, compared 234 
with men who had a BMI of 23.0-24.9 kg/m2. These results are consistent with our results, 235 
although Williams calculated the BMI with a self-reported weight and cumulative incidence 236 
of hypertension at 2 points (baseline and 7 years later), and Matsuo et al. studied middle-aged 237 
male employees. 238 
The exact mechanism by which stable adiposity raises BP is uncertain. However, a likely 239 
explanation is that obesity-associated hypertension appears to be due to inadequate 240 
vasodilatation in the setting of increased blood volume and cardiac output. A defect in control 241 
  12 
of vascular resistance has been attributed to enhanced activity of the sympathetic nervous 242 
system, abnormal rennin-angiotensin-aldosterone relations, and insulin resistance [27-31]. 243 
The peripheral vascular resistance is increased by adipocytokines (e.g., leptin, TNF-α, RBP4) 244 
[32-34]. 245 
  The study has several strengths. First, the effect of weight change during the follow-up 246 
period was taken into account to investigate the association between long-term weight 247 
stability and future incident risk for hypertension, while many previous epidemiological 248 
studies did not account for these factors. Second, the present study had a large cohort for 249 
which gender, age and BMI stratification analysis was possible. In addition, all blood samples 250 
in each year were measured by the same device, reagents, and quality control programs [35].  251 
  However, there are several limitations. First, the participation rate for the follow-up 252 
examinations was approximately 40%, but the mean SBP and DBP did not differ between 253 
individuals who were and were not followed up. In this context, the potential selection bias 254 
may have been small. Second, the instrument used to measure the blood pressure was 255 
switched from the standard mercury sphygmomanometer to an automatic 256 
sphygmomanometer following 2005. The BP determined by means of an automated 257 
sphygmomanometer method was compared with those determined by a standard mercury 258 
sphygmomanometer method, using 18 859 samples (non-medication participants) in 2004 259 
and 2005. Comparability between BP measured using the 2 sphygmomanometers was 260 
acceptable (SBP: r = 0.69, DBP: r = 0.55, P < 0.05, respectively). Third, we could not assess 261 
the potential confounding variables such as fat distribution, physical activity, nutritional 262 
status (e.g., sodium intake), and family history of hypertension.  263 
  In conclusion, the baseline BMI is associated with a future incident risk for hypertension, 264 
even after accounting for weight change during the follow-up period. Weight loss may be 265 
recommended for obese non-hypertensive individuals to prevention incident hypertension 266 
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among men and women who are middle-aged and older. 267 
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Figure legend 372 
Figure 1 373 
Abbreviations: HRs, hazard ratios; CIs, confidence intervals. Age-adjusted HRs with 95% 374 
confidence intervals were adjusted for age (years) in 1998 and sex. Multivariate HRs with 375 
95% confidence intervals were adjusted for possible confounders measured in 1998: age 376 
(years), sex, systolic blood pressure (mmHg), diastolic blood pressure (mmHg), fasting status 377 
(yes or no), total cholesterol level (mmol/liter), high density lipoprotein cholesterol level 378 
(mmol/liter), log-transformed triglyceride level (mmol/liter), lipid medication use (yes or no), 379 
blood glucose status (normal, border, hyperglycemia), diabetic medication use (yes or no), 380 
smoking status (never, ex-, < 20 cigarettes/day, or ≥ 20 cigarettes/day), and alcohol intake 381 
(never, sometimes, < 66 g/day, or ≥ 66 g/day). Bold values showed statistical significance 382 
(P < 0.05).383 
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Table 1. Baseline characteristics of participants by body mass index (BMI) categories 
Gender and baseline variables 
Body mass index, kg/m2 
P-value 
< 19.0 19.0 - 20.9 21.0 - 22.9 23.0 - 24.9 25.0 - 26.9 27.0 - 29.9 > 30.0 
Men (n = 18 336) 
               
 
No. of subjects 1 545  3 476  4 934 4 544 2 598 1 085 154 
 
 
Age, years 63.5  (9.5) 60.5  (10.2) 58.8  (10.3) 57.7  (10.2) 56.5  (10.0) 56.6  (9.8) 55.3  (10.0) <.001 
 
Change in body mass index, kg/m2 0.0  (1.1) 0.1  (1.2) 0.0  (1.2) -0.1  (1.3) -0.2  (1.3) -0.4  (1.5) -0.7  (1.5) <.001 
 
Systolic blood pressure, mmHg 119.9  (11.4) 121.7  (10.8) 122.7  (10.2) 124.0  (9.5) 124.4  (9.4) 125.4  (9.2) 126.2  (8.8) <.001 
 
Diastolic blood pressure, mmHg 71.9  (8.4) 73.1  (8.0) 74.1  (7.9) 75.4  (7.3) 75.9  (7.4) 76.6  (7.1) 78.1  (7.8) <.001 
 
Total cholesterol, mmol/liter 4.7  (0.8) 4.8  (0.8) 5.0  (0.8) 5.1  (0.9) 5.2  (0.8) 5.2  (0.9) 5.2  (0.9) <.001 
 
HDL cholesterol, mmol/liter 1.6  (0.4) 1.5  (0.4) 1.4  (0.4) 1.3  (0.3) 1.2  (0.3) 1.1  (0.3) 1.1  (0.3) <.001 
 
Triacylglycerol, mmol/liter 1.1  (0.5) 1.2  (0.7) 1.5  (0.8) 1.8  (1.0) 2.0  (1.2) 2.2  (1.3) 2.2  (1.0) <.001 
 
Lipid medication use, % 3.2  2.8  2.6  3.1  3.2  3.1  2.6  <.001 
 
Diabetic medication use, % 0.4  0.8  1.0  1.3  1.2  1.4  2.6  0.177  
 
Blood glucose status, % 
              
0.866  
 
  Normal 81.9  83.9  84.3  84.6  81.9  82.0  83.8  
 
 
  Border 13.6  12.4  12.0  11.4  13.5  12.7  9.7  
 
 
  Hyperglycemia 4.5  3.7  3.7  4.0  4.5  5.3  6.5  
 
 
Smoking status, % 
              
0.116  
 
  Never 19.4  20.6  22.4  25.1  24.1  23.3  25.3  
 
 
  Ex 23.4  23.3  27.0  28.1  29.5  33.9  27.9  
 
 
  Current 
               
 
    < 20 cigarettes/day 22.8  18.7  15.3  12.3  11.5  9.8  9.7  
 
 
    ≥ 20 cigarettes/day 34.4  37.4  35.3  34.4  34.9  33.0  37.0  
 
 
Alcohol intake, % 
              
<.001 
 
 Never 48.5  40.6  37.2  36.6  37.6  38.2  51.3  
 
 
 Sometimes 11.5  13.2  13.6 15.1  15.9  18.8  17.5  
 
 
 Everyday 
               
 
    < 66 g/day 36.6  41.9  44.0  43.4  41.4  37.1  25.3  
 
      ≥ 66 g/day 3.4  4.3  5.1  5.0  5.1  5.8  5.8    
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Table 1. Baseline characteristics of participants by body mass index (BMI) categories (continued) 
Gender and baseline variables 
Body mass index, kg/m2 
P-value 
< 19.0 19.0 - 20.9 21.0 - 22.9 23.0 - 24.9 25.0 - 26.9 27.0 - 29.9 > 30.0 
Women (n = 49 869)                             
 
No. of subjects 3 796 9 391 13 824 11 887 6 781 3 434 756 
 
 
Age, years 56.8 (10.9) 54.1  (10.1) 54.4  (9.7) 55.1  (9.5) 56.0  (9.4) 56.1  (9.4) 55.4  (9.2) <.001 
 
Change in body mass index, kg/m2 0.2 (1.2) 0.1  (1.2) 0.0  (1.3) -0.1  (1.4) -0.2  (1.5) -0.3  (1.6) -0.6  (2.0) <.001 
 
Systolic blood pressure, mmHg 117.6 (11.9) 118.5  (11.5) 120.0  (11.1) 121.3  (10.7) 122.7  (10.2) 123.8  (9.8) 124.7  (8.9) <.001 
 
Diastolic blood pressure, mmHg 70.0 (8.5) 70.9  (8.3) 72.1  (8.1) 73.3  (7.9) 74.3  (7.6) 75.3  (7.5) 76.7  (7.4) <.001 
 
Total cholesterol, mmol/liter 5.1 (0.9) 5.2  (0.9) 5.3  (0.9) 5.4  (0.9) 5.4  (0.9) 5.5  (0.9) 5.5  (0.9) <.001 
 
HDL cholesterol, mmol/liter 1.7 (0.4) 1.6  (0.4) 1.5  (0.4) 1.4  (0.3) 1.4  (0.3) 1.3  (0.3) 1.3  (0.3) <.001 
 
Triacylglycerol, mmol/liter 1.0 (0.5) 1.2  (0.6) 1.3  (0.7) 1.5  (0.9) 1.6  (0.9) 1.8  (1.0) 1.9  (1.0) <.001 
 
Lipid medication use, % 1.7  1.5  2.3  2.9  3.3  3.1  3.2  0.367  
 
Diabetic medication use, % 0.9  1.0 1.5  1.2 1.6  1.8 2.2  <.001 
 
Blood glucose status, % 
              
<.001 
 
  Normal 91.1  92.5 92.6  91.8 90.0  89.1 87.0  
 
 
  Border 7.5  6.1 6.1  6.3 8.0  8.4 9.7  
 
 
  Hyperglycemia 1.3  1.4 1.3  1.9 1.9  2.6 3.3  
 
 
Smoking status, % 
              
<.001 
 
  Never 92.6  94.7  94.7  95.2  94.9  94.5  92.2  
 
 
  Ex 0.6  0.5  0.7  0.5  0.6  0.9  0.9  
 
 
  Current 
               
 
    < 20 cigarettes/day 4.7  3.4  3.2  2.8  2.9  3.0  3.6  
 
 
    ≥ 20 cigarettes/day 2.1  1.5  1.5  1.5  1.6  1.6  3.3  
 
 
Alcohol intake, % 
              
<.001 
 
  Never 90.9  88.7  89.0  89.6  90.2  90.7  90.7  
 
 
  Sometimes 5.2  6.9  7.2  6.8  6.5  6.0  5.4  
 
 
  Everyday 
               
 
    < 66 g/day 3.9  4.2  3.7  3.5  3.3  3.1  3.4  
 
      ≥ 66 g/day - 0.1  0.1  0.1  0.0  0.2  0.4    
HDL = high-density lipoprotein. The means (SD) are shown for continuous variables: age, fasting and non-fasting blood glucose, systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and 
triglycerides. SI conversion factors: blood glucose values were converted to mmol/L by multiply by 0.05551; cholesterols values were converted to mmol/L by multiply by 0.02586; triglycerides values were 
converted to mmol/L by multiply by 0.01129. 
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Table 2. The effect of hazard ratios on hypertension within each of seven BMI categories 
    Baseline BMI categories (kg/cm2) 
    < 19.0 19.0 - 20.9 21.0 - 22.9 23.0 - 24.9 25.0 - 26.9 27.0 - 29.9 > 30.0 
Men, age 40-59 years (n = 8 540)        
 No. of person-years 1 590 5 713 9 042 8 267 4 964 1 952 285 
 No. of hypertension cases 127 434 882 1 048 740 351 61 
 Incidence rates per 1 000 person-years 80  76  98  127  149  180  214  
 Age-adjusted HRs (95% CIs) 1.00  1.01 (0.83-1.23) 1.26 (1.05-1.52) 1.57 (1.31-1.89) 1.81 (1.50-2.19) 2.12 (1.73-2.60) 2.48 (1.83-3.36) 
 Model 1† HRs (95% CIs) 1.00  0.90 (0.74-1.09) 1.05 (0.87-1.27) 1.19 (0.98-1.44) 1.36 (1.16-1.66) 1.52 (1.23-1.89) 1.75 (1.28-2.40) 
 Model 2‡ HRs (95% CIs) 1.00  1.01 (0.59-1.73) 0.97 (0.58-1.65) 1.10 (0.64-1.88) 1.82 (1.04-3.16) 1.83 (1.00-3.35) 2.37 (0.91-6.17) 
 Model 3§ HRs (95% CIs) 1.00  0.95 (0.78-1.15) 1.13 (0.94-1.36) 1.24 (1.03-1.50) 1.42 (1.17-1.73) 1.60 (1.30-1.97) 1.77 (1.29-2.41) 
Men, age 60-79 years (n = 9 796)        
 No. of person-years 3 831 6 982 8 334 6 582 2 937 1 075 101 
 No. of hypertension cases 517 1 177 1 566 1 366 710 314 38 
 Incidence rates per 1 000 person-years 135  169  188  208  242  292  376  
 Age-adjusted HRs (95% CIs) 1.00  1.25 (1.13-1.38) 1.38 (1.25-1.52) 1.51 (1.36-1.67) 1.67 (1.49-1.87) 1.94 (1.69-2.24) 2.24 (1.61-3.11) 
 Model 1† HRs (95% CIs) 1.00  1.15 (1.03-1.27) 1.20 (1.09-1.33) 1.26 (1.13-1.41) 1.35 (1.20-1.53) 1.54 (1.32-1.78) 1.68 (1.20-2.35) 
 Model 2‡ HRs (95% CIs) 1.00  1.01 (0.71-1.44) 1.24 (0.88-1.75) 1.48 (1.03-2.13) 1.52 (0.98-2.37) 2.01 (1.11-3.64) N/A 
 Model 3§ HRs (95% CIs) 1.00  1.11 (1.00-1.22) 1.17 (1.06-1.29) 1.26 (1.14-1.40) 1.34 (1.19-1.51) 1.48 (1.28-1.72) 1.68 (1.21-2.35) 
         
Women, age 40-59 years (n = 32 133)        
 No. of person-years 10 877 32 781 45 716 34 389 16 754 7 410 1 402 
 No. of hypertension cases 496 1 682 2 975 2 969 1 940 1 001 265 
 Incidence rates per 1 000 person-years 46  51  65  86  116  135  189  
 Age-adjusted HRs (95% CIs) 1.00  1.15 (1.04-1.27) 1.40 (1.27-1.54) 1.76 (1.60-1.94) 2.25 (2.04-2.49) 2.56 (2.30-2.86) 3.32 (2.86-3.86) 
 Model 1† HRs (95% CIs) 1.00  1.04 (0.94-1.15) 1.15 (1.05-1.27) 1.33 (1.20-1.46) 1.58 (1.43-1.75) 1.65 (1.48-1.84) 1.90 (1.63-2.22) 
 Model 2‡ HRs (95% CIs) 1.00  1.12 (0.90-1.14) 1.23 (0.99-1.53) 1.59 (1.28-1.98) 1.67 (1.32-2.11) 1.99 (1.52-2.60) 1.86 (1.16-2.98) 
 Model 3§ HRs (95% CIs) 1.00  0.98 (0.89-1.08) 1.12 (1.02-1.23) 1.27 (1.16-1.39) 1.47 (1.33-1.62) 1.55 (1.39-1.73) 1.91 (1.66-2.21) 
Women, age 60-79 years (n = 17 736)        
 No. of person-years 5 535 10 525 15 260 12 907 7 673 3 611 598 
 No. of hypertension cases 790 1 591 2 580 2 569 1 663 940 190 
 Incidence rates per 1 000 person-years 143  151  169  199  217  260  318  
 Age-adjusted HRs (95% CIs) 1.00  1.11 (1.02-1.21) 1.24 (1.14-1.34) 1.42 (1.31-1.54) 1.53 (1.40-1.66) 1.77 (1.61-1.95) 2.07 (1.77-2.43) 
 Model 1† HRs (95% CIs) 1.00  1.04 (0.95-1.13) 1.09 (1.01-1.19) 1.21 (1.11-1.31) 1.25 (1.15-1.37) 1.39 (1.26-1.54) 1.61 (1.37-1.90) 
 Model 2‡ HRs (95% CIs) 1.00  1.04 (0.80-1.35) 1.16 (0.90-1.49) 1.25 (0.96-1.62) 1.35 (1.02-1.80) 1.20 (0.84-1.70) 1.66 (0.82-3.38) 
 Model 3§ HRs (95% CIs) 1.00  1.06 (0.98-1.16) 1.10 (1.02-1.19) 1.22 (1.12-1.32) 1.29 (1.18-1.41) 1.40 (1.27-1.54) 1.72 (1.47-2.01) 
Abbreviations: HRs, hazard ratios; CIs, confidence intervals; N/A, data was not available. 
†Adjusted for age (years), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), fasting status (yes or no), total cholesterol level (mmol/liter), high density lipoprotein 
cholesterol level (mmol/liter), log-transformed triglyceride level (mmol/liter), lipid medication use (yes or no), blood glucose status (normal, border, hyperglycemia), diabetic medication 
use (yes or no), smoking status (never, ex-, < 20 cigarettes/day, or ≥ 20 cigarettes/day), and alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day). 
‡Addition of BMI (kg/m2), total cholesterol level (mmol/liter), high-density lipoprotein cholesterol level (mmol/liter), and log-transformed triglyceride level (mmol/liter) change values 
(the endpoint minus the baseline) to Model 1 for adjustment. 
§Adjusted for time-dependent covariates: age (years), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), fasting status (yes or no), total cholesterol level (mmol/liter), high 
density lipoprotein cholesterol level (mmol/liter), log-transformed triglyceride level (mmol/liter), lipid medication use (yes or no), blood glucose status (normal, border, hyperglycemia), 
diabetic medication use (yes or no), smoking status (never, ex-, < 20 cigarettes/day, or ≥ 20 cigarettes/day), and alcohol intake (never, sometimes, < 66 g/day, or ≥ 66 g/day). 
Bold values showed statistical significance (P < 0.05). 
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